This trial is active, not recruiting.

Condition asthma
Treatment minocycline
Phase phase 2
Sponsor State University of New York - Downstate Medical Center
Start date October 1997
End date March 2008
Trial size 20 participants
Trial identifier NCT00536042, open mino


The tetracycline minocycline has, in addition to its anti-infective properties, anti-inflammatory properties which may be of use in the treatment of asthma. This study evaluates the benefit of minocycline as add-on therapy for adults with asthma.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment

Primary Outcomes

Improvement in FEV1 on spirometry
time frame: one year

Secondary Outcomes

decrease in total serum IgE
time frame: one year
decrease in oral steroid requirements
time frame: one year
improvement in quality of life scores
time frame: one year

Eligibility Criteria

Male or female participants from 18 years up to 75 years old.

Inclusion Criteria: - Adults (ages 18 to 75 yrs) - Mild to severe asthma - History of or current oral steroid use to control asthma atopy Exclusion Criteria: - Pregnant women

Additional Information

Official title Open-Label Trial of the Use of Minocycline as an Anti-Inflammatory Agent in the Treatment of Asthma
Principal investigator Rauno Joks, MD
Description Adult asthmatic (ages 18 to 75 years) with a history of moderate to severe persistent asthma are given minocycline capsules as add-on therapy for treatment of asthma. Treatment is for one year. Dosing begins at 150 mg twice daily and can increase every eight weeks by 50mg BID to a maximum of 250 mg twice daily. This is as per patient tolerance as minocycline can cause dizziness and stomach upset, as well as effects of liver enzymes.Patients undergo routine blood toxicity screens every two months, at which time spirometry is performed Exclusion criteria: pregnant women (adequate contraception in mandated) previous history of hypersensitivity to tetracyclines, chronic liver disease Outcome measures: improvement in FEV1 and other spirometric parameters, decrease in oral steroid requirements, change in total serum IgE, improvement in quality of life
Trial information was received from ClinicalTrials.gov and was last updated in September 2007.
Information provided to ClinicalTrials.gov by State University of New York - Downstate Medical Center.